- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01858753
Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
A Phase II, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
This Phase II, double-blind, randomized, placebo-controlled pilot study is designed to determine whether injection of autologous fibroblasts can increase the mobility (decrease the restriction) of burn scars. The study will assess the effects of azficel-T (autologous fibroblasts) in subjects who have a unilateral burn scar that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:
- An axillary scar causing 20-60% restriction of shoulder adduction
- An anterior elbow scar causing 20-60% restriction of elbow extension
- A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension
Subjects will each receive 2 injections of azficel-T or placebo administered 14 days (± 7 days) apart (depending on cell availability) and will be followed for efficacy (including range of motion measurements, scar pain and ability to perform activities) to Visit 7 and for safety to Visit 9 at 1 year.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
California
-
Sacramento, California, Vereinigte Staaten, 95817
- Univ of California David Medical Center
-
San Diego, California, Vereinigte Staaten, 92103
- Univ of California San Diego
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- Division of Burns and Trauma, Jackson Memorial Hospital
-
-
Illinois
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Richard M. Fairbanks Burn Center
-
-
New York
-
Garden City, New York, Vereinigte Staaten, 11530
- Long Island Plastic Surgical Group
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Health Network
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- Center for Innovation in Restorative Medicine
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Univ of Washington, Harborview Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subject is at least 18 years of age
Subject has a unilateral burn scar of a jointed area (i.e., finger, elbow, shoulder) that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:
- An axillary scar causing 20-60% restriction of shoulder abduction
- An anterior elbow scar causing 20-60% restriction of elbow extension
- A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension
- Subject's burn scar to be treated is <100 sq cm in size
- Injury occurred ≤ 36 months prior to screening
- By the Investigator's assessment, physical therapy will not provide significant continuous improvement to the range of motion of the subject's joint
- Subject agrees to maintain any current physical therapy regimen for the duration of the study
- Subject must be able to provide written informed consent and comply with the study requirements
- Females of childbearing potential must have a negative urine pregnancy test at the screening visit and prior to the first treatment, and must agree to use a reliable means of birth control for the duration of the study
- Subject has healthy, non-scarred post auricular skin area suitable for biopsy
- Subject must have a normal complete blood count (CBC) and chemistry panel within 90 days prior to enrollment
Exclusion Criteria:
- Restrictive burn scars that are primarily classified as keloid scars
- Subjects for whom a post auricular biopsy cannot be collected for azficel-T production
- Sunburn or sun damage in the area that will be used for biopsy
- Plans to initiate any other new scar therapy during the study period
- Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study
- History of active autoimmune disease or organ transplantation
- Diagnosis of cancer, including basal cell carcinoma, unless successfully treated or in remission for a minimum of 6 months
- Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, epidermolysis bullosa, ataxia-telangiectasia, Ehlers Danlos syndrome, etc.
- Active systemic infection
- Requires chronic antibiotic or steroidal therapy
- Any conditions that are considered by the Investigator to be contraindications to biopsy or injection
- Pregnant or lactating women, or women trying to become pregnant during the study
- Subject has any disorder that may prevent compliance, such as history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the Investigator's opinion, interfere with the study
- Presence of other disease or condition that would result in impairment of the range of motion of the extremity, e.g., rheumatoid arthritis or stroke
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Autologous fibroblasts
Autologous fibroblasts grown in culture from skin biopsy taken from patient.
The cells will be injected into the scars to be treated.
|
Andere Namen:
|
Placebo-Komparator: Sterile saline
Sterile saline will be injected into the scar to be evaluated.
|
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage Change From Baseline (CFB) of Range of Motion (ROM) of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Daniel D Lozano, MD, Lehigh Valley Health Network
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- FI-B-003
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Restrictive Burn Scars
-
University of BelgradeNoch keine RekrutierungInsulinresistenz | Brandverletzung | Post-Burn-InsulinresistenzSerbien
-
The University of Texas Medical Branch, GalvestonUniversity of Texas Southwestern Medical Center; United States Army Institute... und andere MitarbeiterAbgeschlossenMuskelschwäche | Muskel; Müdigkeit, Herz | Späte Wirkung von Burn | VerbrennungsrehabilitationVereinigte Staaten
Klinische Studien zur Autologous fibroblasts
-
CliPS Co., LtdAbgeschlossenLimbus-Corneae-Insuffizienz-Syndrom | Limbus HornhautKorea, Republik von
-
Royan InstituteAbgeschlossenAknenarben | Nasolabialfalten | Glabellarfalte | Tiefe Falten auf der StirnIran, Islamische Republik
-
Castle Creek Biosciences, LLC.AbgeschlossenBilaterale NasolabialfaltenfaltenVereinigte Staaten
-
SCARM Institute, Tabriz, IranUnbekanntHautalterung | NasolabialfaltenIran, Islamische Republik
-
Oslo University HospitalUniversity of Copenhagen; Sorlandet Hospital HF; University of Agder; Leiden University... und andere MitarbeiterUnbekanntUrogenitale BilharzioseSüdafrika
-
Istituto Scientifico Romagnolo per lo Studio e...RekrutierungSolider Tumor, nicht näher bezeichnet, ErwachsenerItalien
-
Avita MedicalBiomedical Advanced Research and Development AuthorityBeendetVerbrennungenVereinigte Staaten
-
Robert FerrisImmune Cell Therapy Inc.ZurückgezogenKopf-Hals-Plattenepithelkarzinom (HNSCC)Vereinigte Staaten
-
TakedaAbgeschlossen
-
BayerAbgeschlossen